Disarm Therapeutics

AVI BioPharma is a biopharmaceutical company that develops drugs to treat life-threatening diseases using its patented third generation antisense technology. It has completed clinical trials with its NeuGene antisense drugs in more than 300 subjects, addressing cardiovascular restenosis, infectious diseases, cancer, polycystic kidney disease and drug metabolism. Its most advanced cardiovascular program is for restenosis, where it has completed Phase II trials, evaluating its drug, Resten-NG. AVI BioPharma is also in a Phase II clinical trial with a drug for Hepatitis C infection and its influenza A drug candidate has been confirmed to have efficacy against avian influenza H5N1 in preclinical studies. AVI BioPharma maintains a location in Portland, Ore.

Akashi Therapeutics, based in Cambridge, is a global biopharmaceutical company with a focus on developing innovative therapies for individuals affected by rare disorders. The company's mission is to create life-changing treatments that address the unmet medical needs of those living with rare diseases, aiming to improve the quality of life for patients worldwide. Generated from their website's infomation

Rana Therapeutics is a Cambridge-based company that focuses on disease areas, science technology, partnering, sustainable business, and careers. They offer a range of products and services for patients, healthcare professionals, and investors, and are committed to making a positive impact in the healthcare industry. With a strong emphasis on research and development, Rana Therapeutics aims to provide innovative solutions for various diseases. They prioritize accountability and transparency, as evidenced by their financial results, stock information, and press releases. As a reputable company, Rana Therapeutics is dedicated to improving patient outcomes and fostering partnerships within the healthcare community.Generated from the website